Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have been given a consensus rating of “Buy” by the six research firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $17.33.

Several research firms have recently issued reports on TNYA. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday, February 3rd. Chardan Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th.

Institutional Investors Weigh In On Tenaya Therapeutics

Several large investors have recently bought and sold shares of the business. State Street Corp increased its position in Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares during the last quarter. Synovus Financial Corp bought a new stake in Tenaya Therapeutics in the third quarter worth $28,000. SG Americas Securities LLC increased its position in Tenaya Therapeutics by 61.9% in the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after purchasing an additional 15,777 shares during the last quarter. XTX Topco Ltd increased its position in Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares during the last quarter. Finally, Atticus Wealth Management LLC increased its position in Tenaya Therapeutics by 56.3% in the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock worth $68,000 after purchasing an additional 17,199 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Trading Down 6.2 %

NASDAQ TNYA opened at $0.95 on Tuesday. The stock has a market cap of $75.01 million, a price-to-earnings ratio of -0.66 and a beta of 2.84. Tenaya Therapeutics has a 12 month low of $0.68 and a 12 month high of $7.01. The company’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.95.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.